	US 11,717,574 B2
	Therapeutic dendrimers
Marianne Bernice Ashford, Cheshire (GB); Iain Grant, Cheshire (GB); Edward John Hennessy, Waltham, MA (US); William Mccoull, Macclesfield (GB); Michael Giannis, Victoria (AU); Brian Kelly, Victoria (AU); David Owen, Victoria (AU); and John Paul Secrist, Waltham, MA (US)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Södertälje (SE)
Filed on Nov. 11, 2020, as Appl. No. 17/95,043.
Application 17/095,043 is a continuation of application No. 16/376,419, filed on Apr. 5, 2019, granted, now 10,888,624.
Application 16/376,419 is a continuation of application No. 15/899,892, filed on Feb. 20, 2018, granted, now 10,314,920, issued on Jun. 11, 2019.
Claims priority of provisional application 62/591,823, filed on Nov. 29, 2017.
Claims priority of provisional application 62/488,151, filed on Apr. 21, 2017.
Claims priority of provisional application 62/461,983, filed on Feb. 22, 2017.
Prior Publication US 2021/0060172 A1, Mar. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); C08G 69/10 (2006.01); C08G 69/40 (2006.01); C08G 83/00 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); A61K 31/451 (2006.01)

CPC A61K 47/641 (2017.08) [A61K 31/451 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01); C08G 69/10 (2013.01); C08G 69/40 (2013.01); C08G 83/003 (2013.01)]

23 Claims

1. A method of treating cancer comprising administering to a subject in need thereof an effective amount of a dendrimer of formula (III):

D-Core-D (III),

or a pharmaceutically acceptable salt thereof;

wherein,

Core is

AP is an attachment point to another building unit;

W is independently (PM)_cor (H)_e;

Z is independently (L-AA)_aor (H)_e;

PM is PEG_1800-2400;

L-AA is a linker covalently attached to an active agent; wherein L-AA is of the formula:

wherein

A is —N(CH₃);

(c+d) is an integer between 50 and 64; and

provided that if (c+d)<64, then any remaining W and Z groups are (H)_e, wherein e is 64-(c+d); and d is ≥1.